ABBV, 5 DAYS AGO, Collaboration Between AbbVie, Biogen and Pfizer Creates World’s Largest Browsable Resource Linking Rare Protein-Coding Genetic Variants to Human Health and Disease, https://www.nasdaq.com/press-release/collaboration-between-abbvie-biogen-and-pfizer-creates-worlds-largest-browsable-0
ABC, JUN 24, 2021, AmerisourceBergen Announces Date and Time for Third Quarter Fiscal 2021 Earnings Release, https://www.nasdaq.com/press-release/amerisourcebergen-announces-date-and-time-for-third-quarter-fiscal-2021-earnings
ABCL, 1 DAY AGO, AbCellera Appoints Neil Berkley as Chief Business Officer, https://www.nasdaq.com/press-release/abcellera-appoints-neil-berkley-as-chief-business-officer-2021-07-13
ABCM, 1 DAY AGO, Abcam opens new US facility in Boston, MA, https://www.nasdaq.com/press-release/abcam-opens-new-us-facility-in-boston-ma-2021-07-13
ABEO, JUL 7, 2021, Abeona Therapeutics Announces Updated EB-101 Phase 1/2a Clinical Results in Recessive Dystrophic Epidermolysis Bullosa at the Society for Pediatric Dermatology 46th Annual Meeting, https://www.nasdaq.com/press-release/abeona-therapeutics-announces-updated-eb-101-phase-1-2a-clinical-results-in-recessive
ABIO, 1 DAY AGO, ARCA biopharma Provides Update on ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19, https://www.nasdaq.com/press-release/arca-biopharma-provides-update-on-aspen-covid-19-phase-2b-clinical-trial-evaluating
ABMD, JUN 29, 2021, FDA Grants Highest Level of Approval to the Next Generation of Impella RP to Treat Right Heart Failure, https://www.nasdaq.com/press-release/fda-grants-highest-level-of-approval-to-the-next-generation-of-impella-rp-to-treat
ABT, JUN 30, 2021, Abbott's XIENCE Stent Receives FDA Approval for Shortest Blood Thinner Course for High Bleeding Risk Patients, https://www.nasdaq.com/press-release/abbotts-xience-stent-receives-fda-approval-for-shortest-blood-thinner-course-for-high
ABUS, JUL 7, 2021, Arbutus Receives Authorization to Proceed with an Investigational New Drug Application (IND) for AB-729, its Proprietary Subcutaneously-Delivered RNAi Agent, https://www.nasdaq.com/press-release/arbutus-receives-authorization-to-proceed-with-an-investigational-new-drug
ACAD, 3 HOURS AGO, Acadia Pharmaceuticals to Present New Scientific Data on Pimavanserin in Neurodegenerative Diseases at the Alzheimer’s Association International Conference 2021 (AAIC), https://www.nasdaq.com/press-release/acadia-pharmaceuticals-to-present-new-scientific-data-on-pimavanserin-in-0
ACER, 6 DAYS AGO, 50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021, https://www.nasdaq.com/press-release/50-companies-to-present-at-the-access-to-giving-virtual-investor-conference-on-july-0
ACET, JUN 28, 2021, Adicet Bio Added to the Russell 2000® Index, https://www.nasdaq.com/press-release/adicet-bio-added-to-the-russell-2000r-index-2021-06-28
ACHC, 2 DAYS AGO, Acadia Healthcare Announces Date for Second Quarter 2021 Earnings Release, https://www.nasdaq.com/press-release/acadia-healthcare-announces-date-for-second-quarter-2021-earnings-release-2021-07-12
ACHV, JUN 29, 2021, Achieve Announces Completion of Target Enrollment of 750 Subjects in Phase 3 ORCA-2 Smoking Cessation Trial of Cytisinicline, https://www.nasdaq.com/press-release/achieve-announces-completion-of-target-enrollment-of-750-subjects-in-phase-3-orca-2
ACIU, JUN 25, 2021, AC Immune Holds its Annual General Meeting of Shareholders, https://www.nasdaq.com/press-release/ac-immune-holds-its-annual-general-meeting-of-shareholders-2021-06-25
ACOR, JUN 16, 2021, Acorda Therapeutics Announces Repayment of Convertible Senior Notes, https://www.nasdaq.com/press-release/acorda-therapeutics-announces-repayment-of-convertible-senior-notes-2021-06-16
ACRS, 6 DAYS AGO, Aclaris Therapeutics to Participate in the William Blair Biotech Focus Conference 2021, https://www.nasdaq.com/press-release/aclaris-therapeutics-to-participate-in-the-william-blair-biotech-focus-conference
ACRX, 4 HOURS AGO, AcelRx Enters into Licensing Agreement for DZUVEO® in Europe and In-licensing Agreement for Two Products in the U.S., https://www.nasdaq.com/press-release/acelrx-enters-into-licensing-agreement-for-dzuveor-in-europe-and-in-licensing
ACST, JUN 22, 2021, Acasti Pharma Provides Fiscal 2021 Year-End Business Update, https://www.nasdaq.com/press-release/acasti-pharma-provides-fiscal-2021-year-end-business-update-2021-06-22
ADAP, MAY 19, 2021, Two Complete Responses and Response Rate of 41% for People with Synovial Sarcoma Reported at ASCO in Adaptimmune’s Phase 2 SPEARHEAD-1 Trial, https://www.nasdaq.com/press-release/two-complete-responses-and-response-rate-of-41-for-people-with-synovial-sarcoma
ADCT, JUN 22, 2021, ADC Therapeutics Announces Encouraging Interim Results from Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) Presented at the 16th Annual International Conference on Malignant Lymphoma, https://www.nasdaq.com/press-release/adc-therapeutics-announces-encouraging-interim-results-from-pivotal-phase-2-clinical
ADIL, JUL 7, 2021, Adial Announces $5,000,000 Above Market Private Placement at $3.00 Per Share, https://www.nasdaq.com/press-release/adial-announces-%245000000-above-market-private-placement-at-%243.00-per-share-2021-07-07
ADILW, nan, nan, nan
ADMA, JUN 14, 2021, ADMA Biologics to Participate in the Raymond James Human Health Innovation Virtual Conference, https://www.nasdaq.com/press-release/adma-biologics-to-participate-in-the-raymond-james-human-health-innovation-virtual
ADMP, 1 DAY AGO, Adamis Urges Stockholders to Vote to Reelect the Company’s Board of Directors at Upcoming Annual Meeting on Friday, July 16th, https://www.nasdaq.com/press-release/adamis-urges-stockholders-to-vote-to-reelect-the-companys-board-of-directors-at
ADMS, 4 DAYS AGO, Adamas Announces New Employment Inducement Grant, https://www.nasdaq.com/press-release/adamas-announces-new-employment-inducement-grant-2021-07-09
ADPT, 1 DAY AGO, Adaptive Biotechnologies to Report Second Quarter Financial Results on August 4, 2021, https://www.nasdaq.com/press-release/adaptive-biotechnologies-to-report-second-quarter-financial-results-on-august-4-2021
ADTX, 2 DAYS AGO, Aditxt Launches High-Sensitivity Neutralizing Antibody Test to Detect Individual Immune Response to COVID-19, https://www.nasdaq.com/press-release/aditxt-launches-high-sensitivity-neutralizing-antibody-test-to-detect-individual
ADUS, 1 DAY AGO, Addus HomeCare Signs Definitive Agreement To Acquire Armada Skilled Home Health and Hospice in New Mexico, https://www.nasdaq.com/press-release/addus-homecare-signs-definitive-agreement-to-acquire-armada-skilled-home-health-and
ADVM, JUL 1, 2021, Adverum Announces Appointment of Jon Williams, Ph.D., as Vice President, Clinical Affairs, https://www.nasdaq.com/press-release/adverum-announces-appointment-of-jon-williams-ph.d.-as-vice-president-clinical
ADXN, 6 DAYS AGO, 50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021, https://www.nasdaq.com/press-release/50-companies-to-present-at-the-access-to-giving-virtual-investor-conference-on-july-0
ADXS, JUL 6, 2021, Advaxis and Biosight Announce Entry into Definitive Merger Agreement, https://www.nasdaq.com/press-release/advaxis-and-biosight-announce-entry-into-definitive-merger-agreement-2021-07-06
AEMD, JUN 24, 2021, Aethlon Medical Announces Fiscal Year End Financial Results and Provides Corporate Update, https://www.nasdaq.com/press-release/aethlon-medical-announces-fiscal-year-end-financial-results-and-provides-corporate-0
AERI, JUN 21, 2021, Aerie Pharmaceuticals Announces Appointment of Frank Estrada, Ed.D., as Director, Salesforce Training, https://www.nasdaq.com/press-release/aerie-pharmaceuticals-announces-appointment-of-frank-estrada-ed.d.-as-director
AEZS, JUN 7, 2021, Aeterna Zentaris Engages Dr. Michael Levy to Support Development of Autoimmune and Inflammatory CNS Disorders Programs, https://www.nasdaq.com/press-release/aeterna-zentaris-engages-dr.-michael-levy-to-support-development-of-autoimmune-and
AFIB, 1 DAY AGO, Acutus Medical, Inc. Announces Proposed Public Offering of Common Stock, https://www.nasdaq.com/press-release/acutus-medical-inc.-announces-proposed-public-offering-of-common-stock-2021-07-12
AFMD, JUL 1, 2021, Affimed Reports First Quarter 2021 Financial Results and Highlights Operational Progress, https://www.nasdaq.com/press-release/affimed-reports-first-quarter-2021-financial-results-and-highlights-operational
AGE, MAY 17, 2021, AgeX Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update, https://www.nasdaq.com/press-release/agex-therapeutics-reports-first-quarter-2021-financial-results-and-provides-business
AGEN, 6 DAYS AGO, Agenus to Participate in Resistance-Focused Oncology Panel at the William Blair Biotech Focus Conference 2021, https://www.nasdaq.com/press-release/agenus-to-participate-in-resistance-focused-oncology-panel-at-the-william-blair
AGIO, JUN 28, 2021, Agios Submits Marketing Authorisation Application to European Medicines Agency for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency, https://www.nasdaq.com/press-release/agios-submits-marketing-authorisation-application-to-european-medicines-agency-for
AGLE, 6 DAYS AGO, Aeglea BioTherapeutics Appoints Jonathan D. Alspaugh as Chief Financial Officer, https://www.nasdaq.com/press-release/aeglea-biotherapeutics-appoints-jonathan-d.-alspaugh-as-chief-financial-officer-2021
AGRX, 6 DAYS AGO, 50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021, https://www.nasdaq.com/press-release/50-companies-to-present-at-the-access-to-giving-virtual-investor-conference-on-july-0
AGTC, 6 DAYS AGO, AGTC to Host Virtual R&D Day on July 22, 2021, https://www.nasdaq.com/press-release/agtc-to-host-virtual-rd-day-on-july-22-2021-2021-07-08
AHCO, 1 DAY AGO, AdaptHealth Corp. Schedules Second Quarter 2021 Financial Results and Conference Call, https://www.nasdaq.com/press-release/adapthealth-corp.-schedules-second-quarter-2021-financial-results-and-conference-call
AHPI, nan, nan, nan
AIH, JUN 24, 2021, Aesthetic Medical International Holdings Group Limited Reports First Quarter 2021 Unaudited Financial Results, https://www.nasdaq.com/press-release/aesthetic-medical-international-holdings-group-limited-reports-first-quarter-2021
AIKI, 1 DAY AGO, AIkido Pharma to Attend the Alzheimer's Association International Conference, https://www.nasdaq.com/press-release/aikido-pharma-to-attend-the-alzheimers-association-international-conference-2021-07
AIM, 5 DAYS AGO, AIM ImmunoTech Announces Phase 2a Human Challenge Trial to Test its Drug Ampligen as an Intranasal Antiviral Prophylactic Therapy, https://www.nasdaq.com/press-release/aim-immunotech-announces-phase-2a-human-challenge-trial-to-test-its-drug-ampligen-as
AKBA, JUL 1, 2021, Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), https://www.nasdaq.com/press-release/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2021-5
AKER, nan, nan, nan
AKRO, 4 HOURS AGO, Akero Therapeutics Appoints Judy Chou, Ph.D., to its Board of Directors, https://www.nasdaq.com/press-release/akero-therapeutics-appoints-judy-chou-ph.d.-to-its-board-of-directors-2021-07-14
AKTX, JUL 7, 2021, Akari Therapeutics Announces Private Placement, https://www.nasdaq.com/press-release/akari-therapeutics-announces-private-placement-2021-07-07
AKU, JUN 25, 2021, Alliance Healthcare Services Announces Acquisition by and Integration With Akumin, https://www.nasdaq.com/press-release/alliance-healthcare-services-announces-acquisition-by-and-integration-with-akumin
AKUS, MAY 13, 2021, Akouos Reports First Quarter 2021 Financial Results and Provides Business Updates, https://www.nasdaq.com/press-release/akouos-reports-first-quarter-2021-financial-results-and-provides-business-updates
ALBO, 6 DAYS AGO, Albireo to Present at the William Blair Biotech Focus Conference 2021, https://www.nasdaq.com/press-release/albireo-to-present-at-the-william-blair-biotech-focus-conference-2021-2021-07-08
ALC, JUN 28, 2021, Alcon Announces Executive Committee Changes, https://www.nasdaq.com/press-release/alcon-announces-executive-committee-changes-2021-06-28
ALDX, JUL 1, 2021, Aldeyra Therapeutics Joins the Russell 2000® and Russell 3000® Indexes, https://www.nasdaq.com/press-release/aldeyra-therapeutics-joins-the-russell-2000r-and-russell-3000r-indexes-2021-07-01
ALEC, JUL 2, 2021, Alector and GSK announce global collaboration in immuno-neurology for two clinical stage first-in-class monoclonal antibodies for neurodegenerative diseases, https://www.nasdaq.com/press-release/alector-and-gsk-announce-global-collaboration-in-immuno-neurology-for-two-clinical
ALGN, JUL 1, 2021, Align Technology to Announce Second Quarter 2021 Results on July 28, 2021, https://www.nasdaq.com/press-release/align-technology-to-announce-second-quarter-2021-results-on-july-28-2021-2021-07-01
ALGS, JUN 30, 2021, Aligos Therapeutics Announces Pricing of $83.6 Million Public Offering of Common Stock, https://www.nasdaq.com/press-release/aligos-therapeutics-announces-pricing-of-%2483.6-million-public-offering-of-common
ALIM, MAY 27, 2021, 35 of the Best Ideas Companies to Present at the Summer Solstice - Best Ideas from the Buy-Side Virtual Investor Conference on June 1-4, 2021, https://www.nasdaq.com/press-release/35-of-the-best-ideas-companies-to-present-at-the-summer-solstice-best-ideas-from-the
ALKS, 1 DAY AGO, Alkermes Presented New Data Analysis on Healthcare Resource Use Among Veterans With Alcohol Dependence, https://www.nasdaq.com/press-release/alkermes-presented-new-data-analysis-on-healthcare-resource-use-among-veterans-with-0
ALLK, JUN 7, 2021, Allakos Completes Patient Enrollment in Phase 3 Eosinophilic Gastritis and/or Eosinophilic Duodenitis and Phase 2/3 Eosinophilic Esophagitis Clinical Trials of Lirentelimab (AK002), https://www.nasdaq.com/press-release/allakos-completes-patient-enrollment-in-phase-3-eosinophilic-gastritis-and-or
ALLO, 2 DAYS AGO, Allogene Therapeutics Announces Participation in Two Upcoming Virtual Investor Conferences, https://www.nasdaq.com/press-release/allogene-therapeutics-announces-participation-in-two-upcoming-virtual-investor-0
ALNA, 13 HOURS AGO, Allena Pharmaceuticals Announces $28 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules, https://www.nasdaq.com/press-release/allena-pharmaceuticals-announces-%2428-million-registered-direct-offering-priced-at-the
ALNY, JUN 30, 2021, Alnylam Initiates KARDIA-1 Phase 2 Study of Zilebesiran (ALN-AGT) in Patients with Mild-to-Moderate Hypertension, https://www.nasdaq.com/press-release/alnylam-initiates-kardia-1-phase-2-study-of-zilebesiran-aln-agt-in-patients-with-mild
ALPN, JUN 30, 2021, Alpine Immune Sciences to Collaborate with Merck on Immuno-Oncology Study to Evaluate ALPN-202 in Combination with KEYTRUDA® (pembrolizumab), https://www.nasdaq.com/press-release/alpine-immune-sciences-to-collaborate-with-merck-on-immuno-oncology-study-to-evaluate
ALRN, 6 DAYS AGO, Aileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2021, https://www.nasdaq.com/press-release/aileron-therapeutics-to-participate-in-fireside-chat-at-the-william-blair-biotech
ALT, JUN 29, 2021, Altimmune Announces Update on AdCOVID™ Phase 1 Clinical Trial, https://www.nasdaq.com/press-release/altimmune-announces-update-on-adcovidtm-phase-1-clinical-trial-2021-06-29
ALVR, MAY 6, 2021, AlloVir Reports First Quarter 2021 Financial Results, https://www.nasdaq.com/press-release/allovir-reports-first-quarter-2021-financial-results-2021-05-06
ALXN, 3 HOURS AGO, Accelerating Results for Patients, https://www.nasdaq.com/press-release/accelerating-results-for-patients-2021-07-14
ALXO, JUL 3, 2021, ALX Oncology Announces New Data from ASPEN-01, the Phase 1b Study of ALX148, Showing Robust Objective Response in Patients with Gastric or Gastroesophageal Junction Cancer, https://www.nasdaq.com/press-release/alx-oncology-announces-new-data-from-aspen-01-the-phase-1b-study-of-alx148-showing-0
AMED, 1 DAY AGO, Amedisys to Open Westchester County Home Health Care Center, https://www.nasdaq.com/press-release/amedisys-to-open-westchester-county-home-health-care-center-2021-07-13
AMGN, 4 HOURS AGO, Amgen And The International Federation of Psoriasis Associations Launch UPLIFT Innovation Challenge, https://www.nasdaq.com/press-release/amgen-and-the-international-federation-of-psoriasis-associations-launch-uplift
AMPE, 3 HOURS AGO, Ampio Pharmaceuticals, Inc. to Report Fiscal 2021 Second Quarter Financial Results and Provide Corporate Business Update, https://www.nasdaq.com/press-release/ampio-pharmaceuticals-inc.-to-report-fiscal-2021-second-quarter-financial-results-and
AMPH, JUN 15, 2021, Amphastar Pharmaceuticals to Present at the Raymond James Human Health Innovation Conference, https://www.nasdaq.com/press-release/amphastar-pharmaceuticals-to-present-at-the-raymond-james-human-health-innovation
AMRN, JUN 2, 2021, Further Insights into Mechanism of Action of Icosapent Ethyl and Its Unique Form of Eicosapentaenoic Acid (EPA) Presented at the European Atherosclerosis Society (EAS) Congress 2021, https://www.nasdaq.com/press-release/further-insights-into-mechanism-of-action-of-icosapent-ethyl-and-its-unique-form-of
AMRX, JUN 17, 2021, Amneal Announces U.S. FDA Filing Acceptance of Biologics License Application (BLA) for Bevacizumab, https://www.nasdaq.com/press-release/amneal-announces-u.s.-fda-filing-acceptance-of-biologics-license-application-bla-for
AMS, MAY 13, 2021, American Shared Hospital Services Reports First Quarter 2021 Financial Results, https://www.nasdaq.com/press-release/american-shared-hospital-services-reports-first-quarter-2021-financial-results-2021
AMTI, 5 DAYS AGO, Applied Molecular Transport Presents Additional Positive Data from Oral AMT-101 Phase 1b in Ulcerative Colitis at ECCO ‘21 Virtual Congress, https://www.nasdaq.com/press-release/applied-molecular-transport-presents-additional-positive-data-from-oral-amt-101-phase
AMYT, 2 DAYS AGO, Amryt to Report Q2 2021 Results and Host Conference Call & Webcast on August 6, https://www.nasdaq.com/press-release/amryt-to-report-q2-2021-results-and-host-conference-call-webcast-on-august-6-2021-07
ANAB, MAY 27, 2021, AnaptysBio to Present at the 2021 Jefferies Virtual Healthcare Conference, https://www.nasdaq.com/press-release/anaptysbio-to-present-at-the-2021-jefferies-virtual-healthcare-conference-2021-05-27
ANCN, nan, nan, nan
ANGN, JUN 29, 2021, Angion Announces Results from the Phase 2 ALI-201 Study in Patients with COVID-19 Associated Pneumonia, https://www.nasdaq.com/press-release/angion-announces-results-from-the-phase-2-ali-201-study-in-patients-with-covid-19
ANGO, 1 DAY AGO, AngioDynamics Reports Fiscal 2021 Fourth Quarter and Full-Year Financial Results, https://www.nasdaq.com/press-release/angiodynamics-reports-fiscal-2021-fourth-quarter-and-full-year-financial-results-2021
ANIK, JUL 1, 2021, First Anika WristMotion® Total Wrist Arthroplasty Surgery Performed, https://www.nasdaq.com/press-release/first-anika-wristmotionr-total-wrist-arthroplasty-surgery-performed-2021-07-01
ANIP, JUL 6, 2021, ANI Pharmaceuticals Announces Refiling of Cortrophin sNDA with FDA, https://www.nasdaq.com/press-release/ani-pharmaceuticals-announces-refiling-of-cortrophin-snda-with-fda-2021-07-06
ANIX, MAY 26, 2021, Anixa Biosciences Announces Support from the National Cancer Institute for Ovarian Cancer Vaccine Developed by Cleveland Clinic, https://www.nasdaq.com/press-release/anixa-biosciences-announces-support-from-the-national-cancer-institute-for-ovarian
ANNX, JUN 16, 2021, Annexon to Present at the Raymond James Human Health Innovation Conference, https://www.nasdaq.com/press-release/annexon-to-present-at-the-raymond-james-human-health-innovation-conference-2021-06-16
ANPC, JUN 18, 2021, AnPac Bio’s First Disease Treatment Patent Granted, and Its Cancer Treatment Project Secured Multi-Million Dollar Funds, https://www.nasdaq.com/press-release/anpac-bios-first-disease-treatment-patent-granted-and-its-cancer-treatment-project
ANTM, 3 HOURS AGO, Hispanic/Latino Communities Lead Telehealth Visits for Mental Health Services During COVID-19, https://www.nasdaq.com/press-release/hispanic-latino-communities-lead-telehealth-visits-for-mental-health-services-during
ANVS, JUN 10, 2021, Annovis Bio to Present at 2021 BIO Digital, https://www.nasdaq.com/press-release/annovis-bio-to-present-at-2021-bio-digital-2021-06-10
APEN, JUN 14, 2021, MERIT Study Investigators Announce Successful Achievement of the Study's Primary Efficacy & Safety Endpoints, https://www.nasdaq.com/press-release/merit-study-investigators-announce-successful-achievement-of-the-studys-primary
APLS, 6 DAYS AGO, Apellis Announces Agreements to Exchange Approximately $198.6 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock, https://www.nasdaq.com/press-release/apellis-announces-agreements-to-exchange-approximately-%24198.6-million-in-principal
APLT, JUN 28, 2021, Applied Therapeutics Added to Russell Microcap® Index, https://www.nasdaq.com/press-release/applied-therapeutics-added-to-russell-microcapr-index-2021-06-28
APM, 2 DAYS AGO, Aptorum Group Announces Further Positive Interim Results of the Phase 1 Clinical Trial of ALS-4 Targeting Staphylococcus aureus, https://www.nasdaq.com/press-release/aptorum-group-announces-further-positive-interim-results-of-the-phase-1-clinical
APOP, JUN 16, 2021, Cellect Biotechnology Files Registration Statement in Connection with Proposed Strategic Merger Agreement with Quoin Pharmaceuticals, https://www.nasdaq.com/press-release/cellect-biotechnology-files-registration-statement-in-connection-with-proposed
APOPW, nan, nan, nan
APRE, JUN 16, 2021, Aprea Therapeutics Announces Phase 1/2 Trial of Eprenetapopt + Venetoclax + Azacitidine in TP53 Mutant AML Meets Complete Remission Primary Efficacy Endpoint, https://www.nasdaq.com/press-release/aprea-therapeutics-announces-phase-1-2-trial-of-eprenetapopt-venetoclax-azacitidine
APT, MAY 24, 2021, ALPHA PRO TECH, LTD.  ANNOUNCES 2021 ANNUAL MEETING OF SHAREHOLDERS TO BE HELD IN VIRTUAL FORMAT ONLY, https://www.nasdaq.com/press-release/alpha-pro-tech-ltd.-announces-2021-annual-meeting-of-shareholders-to-be-held-in
APTO, JUN 11, 2021, Aptose Presents Highlights from EHA During Corporate Update Event, https://www.nasdaq.com/press-release/aptose-presents-highlights-from-eha-during-corporate-update-event-2021-06-11
APTX, 2 DAYS AGO, Aptinyx to Participate in William Blair Biotech Focus Conference 2021, https://www.nasdaq.com/press-release/aptinyx-to-participate-in-william-blair-biotech-focus-conference-2021-2021-07-12
APVO, JUN 30, 2021, Aptevo Therapeutics' Scientists to Present At Virtual Cell Engager Summit, https://www.nasdaq.com/press-release/aptevo-therapeutics-scientists-to-present-at-virtual-cell-engager-summit-2021-06-30
APYX, 1 DAY AGO, Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2021 Financial Results on August 12, 2021, https://www.nasdaq.com/press-release/apyx-medical-corporation-to-release-second-quarter-of-fiscal-year-2021-financial
AQST, JUN 24, 2021, Aquestive Therapeutics Resubmits New Drug Application for Libervant™ (diazepam) Buccal Film, https://www.nasdaq.com/press-release/aquestive-therapeutics-resubmits-new-drug-application-for-libervanttm-diazepam-buccal
ARAV, JUL 7, 2021, Aravive to Participate in Fireside Chat at 2021 William Blair Biotech Focus Conference, https://www.nasdaq.com/press-release/aravive-to-participate-in-fireside-chat-at-2021-william-blair-biotech-focus
ARAY, JUN 24, 2021, Beloved Family Pet's Lung Cancer is Treated with Targeted Radiotherapy Using the Accuray Radixact® System with Synchrony® Technology, https://www.nasdaq.com/press-release/beloved-family-pets-lung-cancer-is-treated-with-targeted-radiotherapy-using-the
ARCT, JUL 6, 2021, Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences, https://www.nasdaq.com/press-release/arcturus-therapeutics-to-present-at-upcoming-investor-and-scientific-conferences-2
ARDS, 1 DAY AGO, Aridis Pharmaceuticals COVID mAb AR-712 Neutralizes SARS-CoV-2 Delta Variant, https://www.nasdaq.com/press-release/aridis-pharmaceuticals-covid-mab-ar-712-neutralizes-sars-cov-2-delta-variant-2021-07
ARDX, JUN 7, 2021, Ardelyx Announces Presentations at ERA-EDTA Virtual Congress 2021, https://www.nasdaq.com/press-release/ardelyx-announces-presentations-at-era-edta-virtual-congress-2021-2021-06-07
ARGX, 11 HOURS AGO, argenx to Host Virtual R&D Day on July 20, 2021, https://www.nasdaq.com/press-release/argenx-to-host-virtual-rd-day-on-july-20-2021-2021-07-14
ARMP, JUL 7, 2021, Armata Pharmaceuticals to Present at the Ladenburg Thalmann 2021 Healthcare Conference, https://www.nasdaq.com/press-release/armata-pharmaceuticals-to-present-at-the-ladenburg-thalmann-2021-healthcare
ARNA, JUN 18, 2021, Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), https://www.nasdaq.com/press-release/arena-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-14
ARPO, JUN 4, 2021, Aerpio Provides Second Update on Aadi Bioscience Presentation at the ASCO 2021 Virtual Meeting, https://www.nasdaq.com/press-release/aerpio-provides-second-update-on-aadi-bioscience-presentation-at-the-asco-2021
ARQT, nan, nan, nan
ARTL, 2 DAYS AGO, Artelo Biosciences Reports Third Quarter Fiscal 2021 Financial Results and Provides Business Update, https://www.nasdaq.com/press-release/artelo-biosciences-reports-third-quarter-fiscal-2021-financial-results-and-provides
ARTLW, nan, nan, nan
ARVN, JUN 7, 2021, Arvinas Participates in Groundbreaking Ceremony for New Space Within Downtown Crossing Development in New Haven, https://www.nasdaq.com/press-release/arvinas-participates-in-groundbreaking-ceremony-for-new-space-within-downtown
ARWR, 5 HOURS AGO, Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Third Quarter Results, https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-to-webcast-fiscal-2021-third-quarter-results-2021-07-14
ASLN, 1 DAY AGO, ASLAN Pharmaceuticals Announces Loan Facility Providing Up to $45 Million From K2 HealthVentures, https://www.nasdaq.com/press-release/aslan-pharmaceuticals-announces-loan-facility-providing-up-to-%2445-million-from-k2
ASMB, JUL 2, 2021, Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), https://www.nasdaq.com/press-release/assembly-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-8
ASND, JUL 6, 2021, Ascendis Pharma A/S Announces Target Enrollment Achieved in the Phase 3 PaTHway Trial of TransCon™ PTH (palopegteriparatide) in Adults with Hypoparathyroidism (HP) and Provides a Comprehensive Global Clinical Program Update, https://www.nasdaq.com/press-release/ascendis-pharma-a-s-announces-target-enrollment-achieved-in-the-phase-3-pathway-trial
ASRT, JUN 4, 2021, Assertio Holdings, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement, https://www.nasdaq.com/press-release/assertio-holdings-inc.-regains-compliance-with-nasdaq-minimum-bid-price-requirement
ATEC, 2 DAYS AGO, ATEC Announces Select Preliminary Second Quarter 2021 Financial Results, https://www.nasdaq.com/press-release/atec-announces-select-preliminary-second-quarter-2021-financial-results-2021-07-12
ATHA, JUL 6, 2021, Athira Pharma Announces Initiation of Open Label Extension Study for LIFT-AD and ACT-AD Clinical Trials of ATH-1017 for Alzheimer’s Disease, https://www.nasdaq.com/press-release/athira-pharma-announces-initiation-of-open-label-extension-study-for-lift-ad-and-act
ATHE, nan, nan, nan
ATHX, 1 DAY AGO, Athersys to Host Second Quarter Financial Results Call, https://www.nasdaq.com/press-release/athersys-to-host-second-quarter-financial-results-call-2021-07-13
ATNF, 2 DAYS AGO, 180 Life Sciences Regains Nasdaq Compliance for Listing Rules 5605(b)(1) and 5605(c)(2), https://www.nasdaq.com/press-release/180-life-sciences-regains-nasdaq-compliance-for-listing-rules-5605b1-and-5605c2-2021
ATNFW, nan, nan, nan
ATNM, JUN 28, 2021, Actinium Pharmaceuticals Announces Inclusion in Russell Microcap® Index, https://www.nasdaq.com/press-release/actinium-pharmaceuticals-announces-inclusion-in-russell-microcapr-index-2021-06-28
ATNX, JUL 6, 2021, Athenex Provides Update from FDA Type A Meeting Regarding Oral Paclitaxel Plus Encequidar for the Treatment of Metastatic Breast Cancer, https://www.nasdaq.com/press-release/athenex-provides-update-from-fda-type-a-meeting-regarding-oral-paclitaxel-plus
ATOS, JUL 7, 2021, Atossa Therapeutics Receives Regulatory Approval To Open Clinical Study of AT-H201 in Australia, https://www.nasdaq.com/press-release/atossa-therapeutics-receives-regulatory-approval-to-open-clinical-study-of-at-h201-in
ATRA, JUL 2, 2021, Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4), https://www.nasdaq.com/press-release/atara-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-6
ATRC, JUL 7, 2021, AtriCure to Announce Second Quarter 2021 Financial Results, https://www.nasdaq.com/press-release/atricure-to-announce-second-quarter-2021-financial-results-2021-07-07
ATRI, MAY 21, 2021, Atrion Corporation Declares Quarterly Cash Dividend, https://www.nasdaq.com/press-release/atrion-corporation-declares-quarterly-cash-dividend-2021-05-21
ATRS, JUL 7, 2021, Antares Pharma to Present at the Ladenburg Thalmann Annual Healthcare Conference, https://www.nasdaq.com/press-release/antares-pharma-to-present-at-the-ladenburg-thalmann-annual-healthcare-conference-2021
ATXI, JUN 14, 2021, Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol, https://www.nasdaq.com/press-release/avenue-therapeutics-receives-complete-response-letter-from-the-fda-for-iv-tramadol-0
AUPH, JUN 30, 2021, Aurinia Awards $250,000 in Grants to Support Patient Navigation Programs, https://www.nasdaq.com/press-release/aurinia-awards-%24250000-in-grants-to-support-patient-navigation-programs-2021-06-30
AUTL, 6 DAYS AGO, Autolus Therapeutics to Report Second Quarter 2021 Financial Results on August 5, 2021, and will Participate in the William Blair Biotech Focus Conference 2021 on July 14, 2021, https://www.nasdaq.com/press-release/autolus-therapeutics-to-report-second-quarter-2021-financial-results-on-august-5-2021
AVDL, JUL 7, 2021, Avadel Pharmaceuticals to Present at the Ladenburg Thalmann Annual Healthcare Conference 2021, https://www.nasdaq.com/press-release/avadel-pharmaceuticals-to-present-at-the-ladenburg-thalmann-annual-healthcare
AVEO, 5 DAYS AGO, AVEO Oncology to Host Key Opinion Leader Webinar on FOTIVDA® (tivozanib) for Relapsed or Refractory Renal Cell Carcinoma, https://www.nasdaq.com/press-release/aveo-oncology-to-host-key-opinion-leader-webinar-on-fotivdar-tivozanib-for-relapsed
AVGR, JUL 6, 2021, Avinger Announces 510(k) Filing for New Pantheris In-Stent Restenosis Indication, https://www.nasdaq.com/press-release/avinger-announces-510k-filing-for-new-pantheris-in-stent-restenosis-indication-2021
AVIR, 2 DAYS AGO, Atea Pharmaceuticals to Present at William Blair Biotech Focus Conference, https://www.nasdaq.com/press-release/atea-pharmaceuticals-to-present-at-william-blair-biotech-focus-conference-2021-07-12
AVNS, 2 DAYS AGO, Avanos Medical, Inc. Appoints Moji James as Senior Vice President & General Counsel, https://www.nasdaq.com/press-release/avanos-medical-inc.-appoints-moji-james-as-senior-vice-president-general-counsel-2021
AVRO, 6 DAYS AGO, AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), https://www.nasdaq.com/press-release/avrobio-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-2021-07-08
AVXL, JUN 28, 2021, Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Improved both Primary Cognitive and Secondary MDS-UPDRS Efficacy Endpoints with Significant Biomarker Correlation in Placebo-Controlled Phase 2 Clinical Trial for the Treatment of Patients wit..., https://www.nasdaq.com/press-release/anavex-life-sciences-announces-anavexr2-73-blarcamesine-improved-both-primary
AWH, 6 DAYS AGO, Aspira Women’s Health Inc. Announces Coverage for OVA1® in the AIM Specialty Health Laboratory Medicine Clinical Guidelines, https://www.nasdaq.com/press-release/aspira-womens-health-inc.-announces-coverage-for-ova1r-in-the-aim-specialty-health
AXGN, 5 HOURS AGO, Axogen, Inc. to Report Second Quarter Financial Results and Host Conference Call on August 4, 2021, https://www.nasdaq.com/press-release/axogen-inc.-to-report-second-quarter-financial-results-and-host-conference-call-on
